Shun Lü

36.8k total citations · 9 hit papers
431 papers, 11.0k citations indexed

About

Shun Lü is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shun Lü has authored 431 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 306 papers in Pulmonary and Respiratory Medicine, 270 papers in Oncology and 101 papers in Molecular Biology. Recurrent topics in Shun Lü's work include Lung Cancer Treatments and Mutations (276 papers), Lung Cancer Diagnosis and Treatment (107 papers) and Lung Cancer Research Studies (102 papers). Shun Lü is often cited by papers focused on Lung Cancer Treatments and Mutations (276 papers), Lung Cancer Diagnosis and Treatment (107 papers) and Lung Cancer Research Studies (102 papers). Shun Lü collaborates with scholars based in China, United States and South Korea. Shun Lü's co-authors include Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Wěi Li, Mei Hou, Dan Massey, Chong‐Rui Xu, Yongfeng Yu and Sarayut Lucien Geater and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Shun Lü

404 papers receiving 10.8k citations

Hit Papers

Afatinib versus cisplatin... 2014 2026 2018 2022 2014 2017 2019 2015 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    2014 1.6k citations Yi‐Long Wu, Caicun Zhou et al. profile →
  2. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    2017 398 citations Luis Paz‐Ares, James Chih‐Hsin Yang et al. Annals of Oncology profile →
  3. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    2019 396 citations Yi Yang, Shun Lü et al. profile →
  4. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    2015 324 citations Jean‐Charles Soria, Enriqueta Felip et al. profile →
  5. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    2019 265 citations Yi‐Long Wu, Shun Lü et al. profile →
  6. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
    2023 263 citations Thomas John, Jonathan W. Goldman et al. profile →
  7. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Shun Lü, Jun Zhao et al. profile →
  8. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
    2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  9. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Shun Lü 7.3k 6.9k 3.3k 1.9k 722 431 11.0k
Rafał Dziadziuszko 6.3k 0.9× 5.8k 0.8× 2.7k 0.8× 1.8k 0.9× 529 0.7× 290 9.0k
Rodryg Ramlau 9.1k 1.2× 8.9k 1.3× 3.1k 0.9× 1.6k 0.8× 778 1.1× 245 12.8k
Edward S. Kim 5.3k 0.7× 5.2k 0.8× 2.9k 0.9× 1.9k 1.0× 691 1.0× 216 9.8k
Claire Watkins 7.8k 1.1× 7.5k 1.1× 2.9k 0.9× 2.1k 1.1× 660 0.9× 42 11.0k
Katsuhiko Naoki 7.5k 1.0× 6.2k 0.9× 5.0k 1.5× 2.7k 1.4× 603 0.8× 125 11.6k
Balázs Halmos 7.6k 1.0× 8.0k 1.2× 4.9k 1.5× 2.2k 1.1× 672 0.9× 280 12.7k
Vassiliki A. Papadimitrakopoulou 7.4k 1.0× 7.7k 1.1× 4.1k 1.2× 2.7k 1.4× 1.0k 1.4× 223 12.7k
Isamu Okamoto 9.4k 1.3× 9.5k 1.4× 4.1k 1.2× 2.0k 1.0× 959 1.3× 383 13.9k
Ji‐Youn Han 8.2k 1.1× 9.6k 1.4× 3.1k 0.9× 2.1k 1.1× 948 1.3× 257 13.1k
Hidefumi Sasaki 7.3k 1.0× 6.4k 0.9× 5.0k 1.5× 2.7k 1.4× 698 1.0× 143 11.9k

Countries citing papers authored by Shun Lü

Since Specialization
Citations

This map shows the geographic impact of Shun Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shun Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shun Lü more than expected).

Fields of papers citing papers by Shun Lü

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shun Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shun Lü. The network helps show where Shun Lü may publish in the future.

Co-authorship network of co-authors of Shun Lü

This figure shows the co-authorship network connecting the top 25 collaborators of Shun Lü. A scholar is included among the top collaborators of Shun Lü based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shun Lü. Shun Lü is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lü, Shun, Lunxu Liu, Rui Li, et al.. (2025). Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study. Clinical Lung Cancer. 26(3). 244–252.e2.
2.
Ye, Jing, Junfeng Hu, Ling Xu, et al.. (2025). Recent advances in silk fibroin-based biomaterials for tissue engineering applications. International Journal of Biological Macromolecules. 322(Pt 2). 146764–146764. 2 indexed citations
3.
Lindsay, Colin R., et al.. (2024). 206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib. Lung Cancer. 190. 107767–107767. 1 indexed citations
4.
Provencio, Mariano, Mark M. Awad, Tina Cascone, et al.. (2024). LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Annals of Oncology. 35. S1239–S1240. 9 indexed citations
5.
Guan, Yanfang, et al.. (2024). SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimation. Frontiers in Genetics. 15. 1381851–1381851. 1 indexed citations
6.
7.
Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations
8.
Lü, Shun, Jonathan W. Goldman, Junko Tanizaki, et al.. (2024). A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).. Journal of Clinical Oncology. 42(16_suppl). TPS8656–TPS8656. 4 indexed citations
9.
Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations
10.
Yu, Yongfeng, Yan Yu, Yan Zhang, et al.. (2024). Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.. Journal of Clinical Oncology. 42(16_suppl). 8089–8089. 3 indexed citations
11.
Yang, James Chih‐Hsin, Jong Seok Lee, Yun Fan, et al.. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9000–LBA9000. 50 indexed citations
12.
Bar, Jair, Shobhit Baijal, Weidong Zhao, et al.. (2023). 1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort. Annals of Oncology. 34. S799–S800. 2 indexed citations
13.
Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →
14.
Awad, Mark M., Patrick M. Forde, Nicolas Girard, et al.. (2023). 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. Annals of Oncology. 34. S731–S731. 14 indexed citations
15.
Zhao, Ruiying, Yunhua Xu, Yedan Chen, et al.. (2023). Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma. npj Precision Oncology. 7(1). 80–80. 3 indexed citations
16.
Liam, Chong Kin, Te‐Chun Hsia, Jianying Zhou, et al.. (2023). Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research. 29(10). 1879–1886. 22 indexed citations
17.
Lü, Shun, Yongfeng Yu, & Yi Yang. (2019). Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. The Oncologist. 24(S1). S21–S30. 27 indexed citations
18.
Niu, Xiaomin, Fatao Liu, Yi Zhou, et al.. (2017). Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. Clinical Cancer Research. 23(17). 5003–5014. 16 indexed citations
19.
Ai, Xinghao, Jingwen Hou, Xiangyun Ye, et al.. (2016). Integrated discovery of FOXO1–DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer. Molecular BioSystems. 13(2). 330–337. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rafał Dziadziuszko Breakdown of academic impact, for papers by Rodryg Ramlau Breakdown of academic impact, for papers by Edward S. Kim Breakdown of academic impact, for papers by Claire Watkins Breakdown of academic impact, for papers by Katsuhiko Naoki Breakdown of academic impact, for papers by Balázs Halmos Breakdown of academic impact, for papers by Vassiliki A. Papadimitrakopoulou Breakdown of academic impact, for papers by Isamu Okamoto Breakdown of academic impact, for papers by Ji‐Youn Han Breakdown of academic impact, for papers by Hidefumi Sasaki
Rankless by CCL
2026